Genmab — Juli 2019
-
Nu er du langt ude nohope. Patentet på Dara løber så hudt jeg visker til 27 og bliver forlænget for SC-delen, når den bliver godkendt. Der er sikkert udviklet andre ting, inden vi når så langt, men Dara-SC vil have så store fordele, at der ikke er risiko for konkurrence, som jeg ser det.
-
Ofatumumab monkey studie to show the mode of action in MS
https://www.frontiersin.org/articles/10.3389/fimmu.2019.01340/full -
@bikube, det udløber i 30
-
det skrev Rachel i et svar for lang tid siden
-
God morgen

-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

